Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis
Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis
复制标题
急性髓系白血病患者双等位基因 CEBPA 基因突变的良好预后：荟萃分析
DOI：
10.1111/ejh.12450
复制
发表时间：
2015-05-01
影响因子：
3.1
通讯作者：
Liu, Zhen-Fang
中科院分区：
文献类型：
--
作者：
Li, Hong-Ying;Deng, Dong-Hong;Liu, Zhen-Fang
目的越来越多的研究表明双等位基因CEBPA（bi-CEBPA）突变与急性髓细胞白血病（AML）患者的预后良好相关，但结果仍不确定。因此，我们提出了一个荟萃分析，以评估双CEBPA突变的AML患者的预后价值。MethodsA全面的文献检索进行到2014年8月寻找合格的研究。合并的风险比（HR）估计和95%的置信区间（95%CI）的总生存期（OS）和无事件生存期（EFS）被用来计算估计effect.ResultsTen研究，共涵盖了6219名受试者被列入本分析。总体而言，双CEBPA突变与AML患者的良好临床结局相关（EFS的HR：0.41，95% CI：0.32-0.52; OS：0.37，95% CI：0.27-0.50），细胞遗传学正常（CN）-AML（EFS的HR：0.38，95% CI：0.29-0.49; OS：0.32，95% CI：0.23-0.43）。当将单等位基因CEBPA（mo CEBPA）突变和野生型CEBPA（wt CEBPA）AML的队列作为参考组时，双CEBPA突变的AML也显示出有益的结果（OS的HR：0.52，95%CI：0.37-0.72）。结论双CEBPA突变与AML患者的预后密切相关，提示双CEBPA突变有可能成为AML患者的一种新的预后指标。
ObjectivesIncreasing number of studies suggested that biallelic CEBPA (bi CEBPA) mutations were associated with favorable prognosis in patients with acute myeloid leukemia (AML), but the results remain inconclusive. We therefore present a meta-analysis to evaluate the prognostic value of bi CEBPA mutations in patients with AML.MethodsA comprehensive literature search was undertaken through August 2014 looking for eligible studies. Pooled hazard ratios (HRs) estimates and 95% confidence intervals (95% CIs) in overall survival (OS) and event-free survival (EFS) were used to calculate estimated effect.ResultsTen studies covering a total of 6219 subjects were included in this analysis. Overall, bi CEBPA mutations were associated with favorable clinical outcome in patients with AML (HR for EFS: 0.41, 95% CI: 0.32-0.52; for OS: 0.37, 95% CI: 0.27-0.50), in cytogenetically normal (CN)-AML (HR for EFS: 0.38, 95% CI: 0.29-0.49; for OS: 0.32, 95% CI: 0.23-0.43). When took the cohort of monoallelic CEBPA (mo CEBPA) mutated and wild-type CEBPA (wt CEBPA) AML as a reference group, bi CEBPA mutated AML also shown beneficial outcomes (HR for OS: 0.52, 95% CI: 0.37-0.72). No significant difference was found between mo CEBPA mutation and wt CEBPA in patients with AML or CN-AML (P>0.05).ConclusionBi CEBPA mutations in patients with AML are strongly associated with a favorable prognosis, which suggested that bi CEBPA mutations would potentially serve as a novel prognostic marker in AML.